Lack of association between genital tract HIV-1 RNA shedding and hormonal contraceptive use in a cohort of Louisiana women

Sexually Transmitted Diseases

Volumn 34, Issue 11, 2007, Pages 870-872

  Clark, Rebecca A ^a,c   Theall, Katherine P ^b   Amedee, Angela M ^a   Dumestre, Jeanne ^a   Wenthold, LuAnn ^a   Kissinger, Patricia J ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

^c HOP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT; RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OUTPATIENT; UNITED STATES;

ADULT; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-SECTIONAL STUDIES; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOUISIANA; PROSPECTIVE STUDIES; RNA, VIRAL; VIRUS SHEDDING;

EID: 37349114815     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3180ca9633     Document Type: Article

References (13)

1. Al-Harthi L, Landay A. HIV in the female genital tract: Viral shedding and mucosal immunity. Clin Obstet Gyn 2001; 44:144-153.
2. Benki S, Mostad SB, Richardson BA, Mandaliya K, Kreiss JK, Overbaugh J. Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis 2004; 189:2192-2201.
3. Ghosh D. Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol 1992; 66:586-590.
4. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al. Hormonal contraception, vitamin a deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
5. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004; 18:205-209.
6. Seck K, Samb N, Tempesta S. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Trans Infect 2001; 77:190-193.
7. Kovacs A, Wasserman SS, Burns D, et al. Determinants for HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601.
8. Kissinger PJ, Amedee A, Clark RA, Dumestre J, Wenthold L, Theall K, Myers L, Farley TA, Martin DH. Trichomonoas vaginalis and HIV Vaginal Shedding. Oral Presentation T0-101 16th ISSTDR. Amsterdam, July 12, 2005.
9. Kissinger PJ, Dumestre J, Clark RA, Wenthold L, Mohammed H, Hagensee ME, Martin DH. Vaginal swabs versus lavage for detection of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis 2005; 32:227-230.
10. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169-2176.
11. Cu-Uvin S, Caliendo AM, Reinert S. et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
12. Goulston CL, McFarland W. Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Infect Dis 1998; 177: 1100-1103.
13. Iversen AK, Larsen AR, Jensen T, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177:1214-1220.